All In Biotech

Drug Trial Radar · NCT06712654

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Feb 28, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
R1 TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Alebund Pharmaceuticals
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.

Conditions

  • Hyperphosphatemia
  • Chronic Kidney Disease Requiring Chronic Dialysis
  • End Stage Renal Disease on Dialysis

Interventions

  • AP306 75 mg BIDDrug

    AP306 75 mg by mouth, twice daily (150 mg/day). Placebo given once daily. Treatment given daily for 8 weeks.

  • AP306 125 mg BIDDrug

    AP306 125 mg by mouth, twice daily (250 mg/day). Placebo given once daily. Treatment given daily for 8 weeks.

  • AP306 150 mg BIDDrug

    AP306 150 mg by mouth, twice daily (300 mg/day). Placebo given once daily. Treatment given daily for 8 weeks.

  • AP306 75 mg TIDDrug

    AP306 75 mg by mouth, three times daily (225 mg/day). Treatment given daily for 8 weeks.

  • AP306 100 mg TIDDrug

    AP306 100 mg by mouth, three times daily (300 mg/day). Treatment given daily for 8 weeks.

  • AP306 125 mg TIDDrug

    AP306 125 mg by mouth, three times daily (375 mg/day). Treatment given daily for 8 weeks.

  • PlaceboDrug

    Placebo given by mouth, three times daily. Treatment given daily for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the ability of AP306 at different fixed doses to lower serum phosphate in participants with hyperphosphatemia receiving maintenance hemodialysisTime frame: 8 weeks

Locations

31 sites in 2 countries. Site status is shown where the registry gives one.

  • Apogee Clinical Research, LLC

    Huntsville, Alabama · Recruiting

  • California Institute of Renal Research

    Chula Vista, California · Recruiting

  • Academic Medical Research Institute

    Los Angeles, California · Recruiting

  • North America Research Institute

    San Dimas, California · Recruiting

  • Colorado Kidney Care

    Denver, Colorado · Recruiting

  • DaVita Clinical Research

    Middlebury, Connecticut · Recruiting

  • PACT Kidney Care

    Orange, Connecticut · Recruiting

  • US Renal Care - Fort Myers South

    Fort Myers, Florida · Recruiting

  • Nephrology & Hypertension Specialists

    Dalton, Georgia · Recruiting

  • St. Clair Nephrology Research

    Shelby, Michigan · Recruiting

  • DaVita Clinical Research Edina

    Edina, Minnesota · Recruiting

  • Johnson County Clinical Trials

    Kansas City, Missouri · Recruiting

  • DaVita Clinical Research

    Las Vegas, Nevada · Recruiting

  • R1 Therapeutics Clinical Trial Site

    Albuquerque, New Mexico · Recruiting

  • NY Kidney & Hypertension Medicine

    Ridgewood, New York · Recruiting

  • US Renal Care - Alexis

    Toledo, Ohio · Recruiting

  • Sunbeam Research

    Greenville, Texas · Recruiting

  • DaVita Clinical Research

    Houston, Texas · Recruiting

  • Gamma Medical Research

    McAllen, Texas · Recruiting

  • US Renal Care - South San Antonio

    San Antonio, Texas · Recruiting

  • US Renal Care - Westover Hills

    San Antonio, Texas · Recruiting

  • DaVita Clinical Research San Antonio

    San Antonio, Texas · Recruiting

  • US Renal Care

    Waxahachie, Texas · Recruiting

  • DaVita Clinical Research Norfolk

    Norfolk, Virginia · Recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Zhengzhou University-First Affiliated Hospital

    Zhengzhou, Henan, China · Recruiting

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China · Recruiting

  • Shanghai Jiao Tong University School of Medicine, Renji Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.